Stability and Tolerability of High Concentrations of Intrathecal Bupivacaine and Opioid Mixtures in Chronic Noncancer Pain: An Open-Label Pilot Study

Pain Medicine

Volumn 11, Issue 11, 2010, Pages 1612-1618

  Goucke, C Roger ^a   Dusci, Leon J ^c   Van Leeuwen, Shane ^b   Fairclough, Denise ^a   Ilett, Ken F ^c,d  

^a Departments of Pain Management   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Path West Laboratory Medicine   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bupivacaine; Chronic Pain; Intrathecal; Stability; Tolerability

Indexed keywords

BUPIVACAINE; HYDROMORPHONE; MORPHINE SULFATE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OSWESTRY DISABILITY INDEX; PAIN ASSESSMENT; PHYSICAL EXAMINATION; VISUAL ANALOG SCALE;

EID: 78149240945     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00958.x     Document Type: Article

References (22)

1. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44:289-300.
2. Bennett G, Serafini M, Burchiel K, et al. Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage 2000;20:S12-36.
3. Walker SM, Goudas LC, Cousins MJ, Carr DB. Combination spinal analgesic chemotherapy: A systematic review. Anesth Analg 2002;95:674-715.
4. Deer TRSM, Buchser E, Ferrante FM, Hassenbusch SJ. Intrathecal bupivacaine for chronic pain: A review of current knowledge. Neuromodulation 2002;5:196-207.
5. Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: An update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004;27:540-63.
6. Deer TKE, Hassenbusch EJ, Burton A, et al. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (Intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007;10:300-28.
7. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: A double blind, randomized, crossover, multicenter study by the national forum of independent pain clinicians (NFIPC). Neuromodulation 2002;5:208-13.
8. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy-a survey of clinical trends and decision making. J Pain Symptom Manage 2000;20:S4-11.
9. Deer TR, Caraway DL, Kim CK, et al. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002;2:274-8.
10. Mironer YE, Grummann S. Experience with alternative solutions in intrathecal treatment of chronic nonmalignant pain. Pain Digest 1999;9:299-302.
11. Lundborg C, Dahm P, Nitescu P, Appelgren L, Curelaru I. Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I). Acta Anaesthesiol Scand 1999;43:667-78.
12. Martindale W. Martindale: The Extra Pharmacopeia. London: Pharmaceutical Press; 1989.
13. Schneider M, Ettlin T, Kaufmann M, et al. Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg 1993;76:1154-7.
14. Pollock JE. Neurotoxicity of local anaesthetics and transient neurological symptoms. Best Pract Res Clin Anaesthesiol 2003;17:471-84.
15. Takenami T, Yagishita S, Murase S, et al. Neurotoxicity of intrathecally administered bupivacaine involves the posterior roots/posterior white matter and is milder than lidocaine in rats. Reg Anesth Pain Med 2005;30:464-72.
16. Perren F, Buchser E, Chedel D, et al. Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain. Pain 2004;109:189-94.
17. Classen AM, Wimbish GH, Kupiec TC. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Management 2004;28:603-11.
18. Hildebrand KR, Elsberry DD, Deer TR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain 2001;17:239-44.
19. Bianchi F, Ginggen A, Tardy Y. Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia 2008;63:972-8.
20. Deer T, Krames ES, Hassenbusch EJ. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (Intraspinal) drug delivery: Report of and interdisciplinary expert panel. Neuromodulation 2007;10:300-28.
21. Kumar K, Bodani V, Bishop S, Tracey S. Use of intrathecal bupivacaine in refractory chronic nonmalignant pain. Pain Med 2009;10:819-28.
22. Buchser E, Durrer A, Chedel D, Mustaki JP. Efficacy of intrathecal bupivacaine: How important is the flow rate? Pain Med 2004;5:248-52.